表紙
市場調査レポート

筋層非浸潤性膀胱癌 (NMIBC) (表在性膀胱癌) :パイプライン製品の分析

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 251532
出版日 ページ情報 英文 141 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
筋層非浸潤性膀胱癌 (NMIBC) (表在性膀胱癌) :パイプライン製品の分析 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2016
出版日: 2016年04月13日 ページ情報: 英文 141 Pages
概要

筋層非浸潤性膀胱癌の代表的な症状には、血尿、頻尿、骨盤の痛みなどがあります。この疾患の要因として、加齢、喫煙などがあります。治療法には、外科手術、化学療法、放射線治療があります。

当レポートでは、筋層非浸潤性膀胱癌 (NMIBC) (表在性膀胱癌) に対する治療薬の開発状況について調査しており、パイプライン製品の概要、治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

  • 調査範囲

筋層非浸潤性膀胱癌 (NMIBC) (表在性膀胱癌) の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

筋層非浸潤性膀胱癌 (NMIBC) (表在性膀胱癌) :企業で開発中の治療薬

筋層非浸潤性膀胱癌 (NMIBC) (表在性膀胱癌) :大学/機関で研究中の治療薬

筋層非浸潤性膀胱癌 (NMIBC) (表在性膀胱癌) :パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

筋層非浸潤性膀胱癌 (NMIBC) (表在性膀胱癌) :企業で開発中の製品

筋層非浸潤性膀胱癌 (NMIBC) (表在性膀胱癌) :大学/機関で研究中の製品

筋層非浸潤性膀胱癌 (NMIBC) (表在性膀胱癌) の治療薬開発に従事している企業

  • Altor BioScience Corporation
  • APIM Therapeutics AS
  • アステラス製薬
  • Bavarian Nordic A/S
  • BioCancell Ltd
  • Celgene Corporation
  • Cold Genesys, Inc.
  • Heat Biologics, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Taris Biomedical LLC
  • Telesta Therapeutics Inc.
  • UroGen Pharmaceuticals, Ltd.
  • Vakzine Projekt Management GmbH
  • Viralytics Ltd.
  • Viventia Bio Inc.

筋層非浸潤性膀胱癌 (NMIBC) (表在性膀胱癌) :治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

筋層非浸潤性膀胱癌 (NMIBC) (表在性膀胱癌) :最近のパイプライン動向

筋層非浸潤性膀胱癌 (NMIBC) (表在性膀胱癌) :休止中のプロジェクト

筋層非浸潤性膀胱癌 (NMIBC) (表在性膀胱癌) :開発が中止された製品

筋層非浸潤性膀胱癌 (NMIBC) (表在性膀胱癌) :製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7848IDB

Summary

Global Markets Direct's, 'Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2016', provides an overview of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
  • The report reviews pipeline therapeutics for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) therapeutics and enlists all their major and minor projects
  • The report assesses Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Overview
  • Therapeutics Development
    • Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Overview
    • Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics under Development by Companies
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics under Investigation by Universities/Institutes
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Products under Development by Companies
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Products under Investigation by Universities/Institutes
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Companies Involved in Therapeutics Development
    • Altor BioScience Corporation
    • APIM Therapeutics AS
    • Astellas Pharma Inc.
    • Bavarian Nordic A/S
    • BioCancell Ltd
    • Celgene Corporation
    • Cold Genesys, Inc.
    • Heat Biologics, Inc.
    • Spectrum Pharmaceuticals, Inc.
    • Taris Biomedical LLC
    • Telesta Therapeutics Inc.
    • UroGen Pharmaceuticals, Ltd.
    • Vakzine Projekt Management GmbH
    • Viralytics Ltd.
    • Viventia Bio Inc.
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ALT-801 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALT-803 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • apaziquone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • APL-1202 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATX-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BC-819 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biologic for Superficial Bladder Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cavatak - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CG-0070 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CV-301 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DAB-389EGF - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • docetaxel - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug for NMIBC - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • erlotinib hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • gemcitabine hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • imiquimod - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lenalidomide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mitomycin SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize EGFR for Superficial Bladder Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rAd-IFN - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sirolimus albumin-bound - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Urocidin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VB-4845 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vesigenurtucel-L - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VPM-1002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Recent Pipeline Updates
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Dormant Projects
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Discontinued Products
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Product Development Milestones
    • Featured News & Press Releases
      • Feb 25, 2016: Heat Biologics Provides Update on Its HS-410 Phase II Monotherapy Bladder Cancer Trial Arm
      • Feb 19, 2016: Spectrum Pharmaceuticals Announces FDA Acceptance of NDA Filing for EOquin (apaziquone for intravesical instillation)
      • Feb 10, 2016: FDA Lifts Heat Biologics Partial Clinical Hold
      • Feb 03, 2016: Heat Biologics Reports Update on Its HS-410 Phase 2 Bladder Cancer Trial
      • Jan 26, 2016: Heat Biologics CSO to Present Interim Results From the Monotherapy Arm in Its Ongoing HS-410 Phase 2 Bladder Cancer Trial at the Phacilitate Immunotherapy World Conference
      • Jan 13, 2016: UroGen Pharma Expands Uro-Oncology Clinical Pipeline with Addition of TLR-7 Agonist Phase 2 Asset
      • Nov 06, 2015: Heat Biologics Reports HS-410 Phase 1 Bladder Cancer Trial Results at the Society for Immunotherapy of Cancer Annual Meeting
      • Nov 03, 2015: Results of Heat Biologics' HS-410 Phase 1 Safety Trial in Non-Muscle Invasive Bladder Cancer to be Presented at SITC Annual Meeting
      • Oct 26, 2015: Spectrum Pharmaceuticals Initiates Apaziquone Pivotal Trial for the Treatment of Non-Muscle Invasive Bladder Cancer Following SPA Agreement
      • Aug 17, 2015: Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment (SPA) for the Upcoming Apaziquone Phase 3 Trial in Patients with Non-Muscle Invasive Bladder Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), H1 2016
  • Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Altor BioScience Corporation, H1 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by APIM Therapeutics AS, H1 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Astellas Pharma Inc., H1 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Bavarian Nordic A/S, H1 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by BioCancell Ltd, H1 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Celgene Corporation, H1 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Cold Genesys, Inc., H1 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Heat Biologics, Inc., H1 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Taris Biomedical LLC, H1 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Telesta Therapeutics Inc., H1 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by UroGen Pharmaceuticals, Ltd., H1 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Vakzine Projekt Management GmbH, H1 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Viralytics Ltd., H1 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Viventia Bio Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics - Recent Pipeline Updates, H1 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Dormant Projects, H1 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), H1 2016
  • Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top